T. Cerny

1.3k total citations
36 papers, 890 citations indexed

About

T. Cerny is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, T. Cerny has authored 36 papers receiving a total of 890 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 9 papers in Molecular Biology. Recurrent topics in T. Cerny's work include Chemotherapy-induced organ toxicity mitigation (11 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). T. Cerny is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (11 papers), Cancer Treatment and Pharmacology (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). T. Cerny collaborates with scholars based in Switzerland, United Kingdom and Italy. T. Cerny's co-authors include A Küpfer, C. Aeschlimann, Martin F. Fey, J. Margison, Michael Lind, B H Lauterburg, N. Thatcher, Cristiana Sessa, Franziska Joncourt and P. M. Wilkinson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

T. Cerny

36 papers receiving 868 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Cerny Switzerland 19 347 337 239 156 110 36 890
M Soukop United Kingdom 19 575 1.7× 234 0.7× 236 1.0× 169 1.1× 68 0.6× 48 1.1k
James Raschko United States 20 416 1.2× 112 0.3× 212 0.9× 179 1.1× 88 0.8× 50 1.1k
Robert J. Cersosimo United States 16 744 2.1× 187 0.6× 319 1.3× 283 1.8× 59 0.5× 43 1.4k
T. Cerny Switzerland 11 310 0.9× 226 0.7× 131 0.5× 150 1.0× 56 0.5× 16 692
Jason A. Sprowl United States 19 747 2.2× 188 0.6× 315 1.3× 108 0.7× 52 0.5× 34 1.2k
A.S.T. Planting Netherlands 19 681 2.0× 254 0.8× 333 1.4× 236 1.5× 26 0.2× 31 1.2k
Diana Stempak Canada 16 254 0.7× 100 0.3× 380 1.6× 202 1.3× 178 1.6× 22 975
O. Christensen Germany 15 484 1.4× 170 0.5× 368 1.5× 286 1.8× 59 0.5× 30 1.1k
Muhammad Salim United States 15 698 2.0× 176 0.5× 260 1.1× 250 1.6× 98 0.9× 42 1.1k
Antonella Savarese Italy 20 587 1.7× 175 0.5× 252 1.1× 171 1.1× 41 0.4× 66 1.5k

Countries citing papers authored by T. Cerny

Since Specialization
Citations

This map shows the geographic impact of T. Cerny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Cerny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Cerny more than expected).

Fields of papers citing papers by T. Cerny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Cerny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Cerny. The network helps show where T. Cerny may publish in the future.

Co-authorship network of co-authors of T. Cerny

This figure shows the co-authorship network connecting the top 25 collaborators of T. Cerny. A scholar is included among the top collaborators of T. Cerny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Cerny. T. Cerny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ess, S.M., Harish C. Phuleria, Martin Früh, et al.. (2013). Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. Swiss Medical Weekly. 143(2324). w13771–w13771. 3 indexed citations
2.
Leyvraz, Serge, Martin Zweifel, Gernot Jundt, et al.. (2006). Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Annals of Oncology. 17(4). 646–651. 23 indexed citations
3.
Joerger, Markus, C. Oehlschlegel, T. Cerny, & Silke Gillessen. (2002). Postradiation High-Grade Myofibroblastic Sarcoma of the Prostate – a Rare Entity of Prostatic Tumors – Responding to Liposomal Doxorubicin. Oncology Research and Treatment. 25(6). 558–561. 3 indexed citations
4.
Cerny, T.. (2000). Die Bedeutung des Lymphknotenbefalls beim Mammakarzinom für den Onkologen. Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie. 125(10). 813–816. 1 indexed citations
5.
Cerny, T., Serge Leyvraz, Thomas von Briel, et al.. (1999). Saturable metabolism of continuous high-dose ifosfamide with Mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Annals of Oncology. 10(9). 1087–1094. 30 indexed citations
6.
Betticher, Daniel, Daniel Ratschiller, S.‐F. Hsu Schmitz, et al.. (1998). Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Annals of Oncology. 9(7). 721–726. 24 indexed citations
7.
Stupp, Roger, Jean Bauer, Olivia Pagani, et al.. (1998). Ventricular arrhythmia and torsade de pointe: Dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. Annals of Oncology. 9(11). 1233–1242. 21 indexed citations
8.
Pagani, Olivia, Cristiana Sessa, Giovanni Martinelli, et al.. (1997). Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer. Annals of Oncology. 8(7). 655–661. 11 indexed citations
9.
10.
Küpfer, A, C. Aeschlimann, & T. Cerny. (1996). Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. European Journal of Clinical Pharmacology. 50(4). 249–252. 86 indexed citations
11.
Sessa, Cristiana, Massimo Zucchetti, T. Cerny, et al.. (1995). Phase I clinical and pharmacokinetic study of oral etoposide phosphate.. Journal of Clinical Oncology. 13(1). 200–209. 23 indexed citations
12.
Küpfer, A, et al.. (1994). Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. The Lancet. 343(8900). 763–764. 132 indexed citations
13.
Cerny, T., et al.. (1993). Depletion of circulating cyst(e)ine by oral and intravenous mesna. British Journal of Cancer. 68(3). 590–593. 26 indexed citations
14.
Lee, Siow Ming, Michael Bromley, Martin Harris, et al.. (1992). Immunohistological examination of the inter- and intracellular distribution of 06-alkylguanine-DNA-alkyltransferase in human liver and melanoma.. UCL Discovery (University College London). 3 indexed citations
15.
Sessa, Cristiana, F. Calabresi, F. Cavalli, et al.. (1991). Phase II studies of 4’-iodo-4’-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers. Annals of Oncology. 2(10). 727–731. 6 indexed citations
16.
Kurowski, Volkhard, T. Cerny, A Küpfer, & Thomas Wagner. (1991). Metabolism and pharmacokinetics of oral and intravenous ifosfamide. Journal of Cancer Research and Clinical Oncology. 117(S4). S148–S153. 39 indexed citations
17.
Sessa, Cristiana, et al.. (1990). A phase II study of iproplatin in advanced or metastatic stomach cancer. European Journal of Cancer and Clinical Oncology. 26(1). 61–62. 1 indexed citations
18.
Lind, Michael, J. Margison, T. Cerny, Nicholas Thatcher, & P. M. Wilkinson. (1989). Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemotherapy and Pharmacology. 25(2). 139–142. 55 indexed citations
19.
Cerny, T., Michael Lind, N. Thatcher, R Swindell, & R. Stout. (1989). A simple outpatient treatment with oral Ifosfamide and oral Etoposide for patients with small cell lung cancer (SCLC). British Journal of Cancer. 60(2). 258–261. 32 indexed citations
20.
Cerny, T., A Pedrazzini, R Joss, & Kurt Brunner. (1988). Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). European Journal of Cancer and Clinical Oncology. 24(11). 1791–1794. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M Soukop Breakdown of academic impact, for papers by James Raschko Breakdown of academic impact, for papers by Robert J. Cersosimo Breakdown of academic impact, for papers by T. Cerny Breakdown of academic impact, for papers by Jason A. Sprowl Breakdown of academic impact, for papers by A.S.T. Planting Breakdown of academic impact, for papers by Diana Stempak Breakdown of academic impact, for papers by O. Christensen Breakdown of academic impact, for papers by Muhammad Salim Breakdown of academic impact, for papers by Antonella Savarese
Rankless by CCL
2026